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Stephanie Halene, M.D., Ph.D. We first optimized engraftment of normal adult hematopoietic stem and progenitor cells (HSPCs) into MISTRG and compared efficiency to the current "gold standard", NSG mice. We subsequently transplanted primary MDS bone marrow cells from patients with high-grade and low grade disease into MISTRG mice and compared engraftment levels and "quality" against engraftment in NSG mice. We optimized T-cell depletion and engraftment; we devised analysis tools, including a targeted exome library amenable to use on mixed human-mouse cell populations, flow-cytometric and histologic characterization; and we established secondary transplantation protocols. We optimized treatment regimens in MDS-MISTRG PDXs including chemotherapeutic and targeted regimens.
Task 1: IRB and HRPO review and approval for studies involving human subjects and IACUC and ACURO review and approval for animal use: Local Internal Review Board and DoD regulatory review and approval of the human subject protocol to harvest bone marrow, peripheral blood, and buccal swab samples from patients were obtained at the start of the funding period.
Local IACUC and DoD regulatory review and approval for the use of animals (mice) were obtained. Task 2. Optimize transplantation of primary MDS bone marrow cells into MISTRG mice: Optimize transplantation of primary MDS bone marrow cells into MISTRG mice by modulating pre-transplant irradiation doses, cell numbers and preparation, transplant route, and age of murine recipients Task 2a. Transplantation of healthy adult stem cells. The goal is to achieve multilineage engraftment levels of human cells > 10% in the mouse bone marrow with high viability of recipients after transplantation. We have based our studies with adult hematopoietic stem and progenitor cells (HSPC) on our prior studies with fetal liver derived HSPC. To assess successful engraftment, we have analyzed engraftment in peripheral blood (PB) and in bone marrow (BM) and spleen at 10-15 weeks after transplant. We have analyzed engraftment by flow cytometric differentiation of human from murine cells and by analyzing human cell subsets based on lineage markers.
(i) Cell numbers and preparation: Fetal liver CD34+ cells are highly proliferative and as few as 3,000 CD34-selected cells can engraft humanized mice. Engraftment occurs in 100% of mice with engraftment levels of >90% in mouse bone marrow when 50,000 fetal liver CD34-selected cells are engrafted. Viability of mice engrafted at >90% is compromised due to development of anemia with viability of ~ 50% 8 weeks after transplant. Thus engraftment levels of ~50% are desirable due to greater survival and sufficiently high engraftment levels to study diseases. We transplanted mice with 100,000 -150,000 adult CD34+ cells and compared engraftment levels in MISTRG mice versus NSG mice, the current gold standard for xenotransplantation assays:
(ii) Pre-transplant Irradiation Dose: MISTRG mice can engraft human cells without irradiation due to suboptimal murine stem cell maintenance secondary to humanization of cytokines. Prior studies have established an irradiation dose of 2x150cGy for engraftment into newborn MISTRG mice. Mice do not exhibit toxicity from this irradiation dose and without transplantation viability is ~100%. Since engraftment with 100,000 -150,000 adult CD34+ cells with prior irradiation of 2x150cGy gave optimal results with engraftment levels between 10-50% we chose 2x150cGy as the optimal for future studies.
(iii) Transplantation route:
Stephanie Halene, M.D., Ph.D. Previous studies have established intrahepatic injection into newborn MISTRG mice as an optimal transplantation route. Intrahepatic injection has several advantages: 1) At time of birth hematopoiesis occurs in the bone marrow and newborn liver with progressive transition from the liver to the bone marrow. The bone marrow niche is primed to accept incoming stem cells, while the liver still continues to provide support for stem cells; this represents an optimal environment for human HSC engraftment into the humanized niche. The niche microenvironment is optimized for stem cell expansion to allow growth of the organism, providing optimal proliferation signals to engrafted stem cells. 2) Engraftment into newborn MISTRG pups is costeffective. MISTRG litters comprise 7-12 pups which are weaned into cages of 3-5mice/cage at 3-4 weeks of age. Viability post transplant is ~50-80%. Engraftment into adult mice retroorbitally requires mice ~ 6 weeks of age and intra-femorally ~8-12 weeks of age due to technical requirements. By injection into newborn mice, maintenance of mice pre-transplant can be avoided with savings of approximated $100-200/litter of ~10 transplant recipients. 3) Intrahepatic transplantation into newborn mice is nearly atraumatic with up to 100% survival post procedure. Injection retro-orbitally into adult mice requires anesthesia, however, it is also rapid with near 100% survival. (Figure 3 ). Histologic analysis reveals periosteal engraftment of CD34+ cells and mature myeloid engraftment in MISTRG that is lacking in NSG mice not only for normal CD34+ cells but also for MDS derived CD34+ cells (Figure 4 ). (i) Cell numbers and preparation: Primary human bone marrow samples vary greatly in "quality" due to 1) patient's disease and bone marrow status and 2) technical quality. Bone marrow for research purposes is taken at the time that the bone marrow procedure is performed for clinical purposes. Optimal sample delivery to the clinical labs is assured.
Cell numbers: primary MDS bone marrow samples vary between 0.3x10 6 to 1x10 9 cells/sample. Clinical factors determining cell number obtained are:
Bone marrow cellularity Presence of absence of fibrosis MDS subtype -lower grade MDS generally yields lower cell numbers that higher grade MDS. Based on our studies, when >1x10 7 mononuclear cells are obtained xenotransplantation of ~5 recipients is feasible. Samples with <1x107 cells are unlikely to yield significant engraftment in a significant number of mice (>/= 5).
Cell preparation: All bone marrow samples are ficolled to obtain the mononuclear cell fraction and cryopreserved in aliquots of 1-5 x10 7 cells/vial; at time of xenotransplantation samples are rapidly thawed and processed for transplantation. Based on our studies and studies by Wunderlich et al. [2] , we pre-incubated primary bone marrow samples with an anti-CD3 antibody to prevent engraftment of alloreactive T-cells. In MISTRG engraftment of T-cells is thus minimized and survival of engrafted mice thus not limited by graft versus host disease.
1) Transplantation of unsorted bone marrow is feasible with pre-incubation of anti-CD3 antibody 2) T-cell depletion and engraftment of the CD3 negative fraction is feasible with or without preincubation of anti-CD3 antibody 3) CD34 selection and engraftment of the CD34-selected fraction gives optimal engraftment results with multilineage hematopoiesis (absent T-cells with pre-incubation with anti-CD3 antibody).
(ii) Pre-transplant Irradiation Dose: Based on studies with normal CD34+ HSPC engraftment a pre-transplant irradiation dose of 2x150cGy administered 4-8 hours apart was chosen.
(iii) Transplantation route: Based on studies with normal CD34+ HSPCs intrahepatic engraftment into newborn MISTRG mice was chosen.
(iv) Age of murine recipients: Based on our studies with fetal liver derived CD34+ cells and adult HSPCs intrahepatic engraftment into newborn mice was chosen. The major risk of intrahepatic injection in newborn mice is rejection by the mom. We have extended the injection time from postnatal day 1 to day 3. MISTRG mice successfully engraft up to day 3 postnatally.
Stephanie Halene, M.D., Ph.D.
Low-and high-grade MDS efficiently engraft in MISTRG but not NSG mice.
Based on these techniques we have established an efficient and reliable MDS xenotransplantation model. Examples of successful MDS xenotransplantation results are given in Figure 5 :
Given the successful engraftment of normal CD34+ HSPCs and first MDS samples, we tested engraftment of primary MDS BM derived CD34+ cells from patients with low and high-grade MDS. With the goal to develop a pre-clinical model we engrafted CD34+ cell numbers based on availability of cells and newborn NSG and MISTRG mice with cell numbers ranging from 5x10 4 -10 6 CD34+ enriched cells/mouse. Whenever available MISTRG and NSG newborn mice were engrafted at the same time. As evident by the data presented in Figure  6 , a minimum of 100,000 CD34+ MDS HSPCs are required for measurable engraftment > 1% (red line) in MISTRG and NSG mice. MISTRG mice promoted significantly higher engraftment in BM and PB (PB not shown). Stephanie Halene, M.D., Ph.D. MDS clonal hematopoiesis is represented and preserved in MISTRG mice. MDS is a clonal disorder of the stem cell. Diseased and normal stem cells can coexist in a patient's bone marrow and normal, healthy stem cells may preferentially engraft and repopulate the murine host in xenotransplantation studies. MDS stem cell are carry genetic aberrations, such as chromosomal rearrangements and gene mutations. To determine whether the patient's disease clone(s) engrafted in MISTRG and NSG mice, we sorted human hematopoietic cells from MISTRG and NSG bone marrow an submitted these to chromosomal and FISH analysis. In addition, we designed a targeted exome library to identify mutations in ~ 200 genes frequently mutated in MDS and other myeloid malignancies (Figure 9 ). MISTRG mice replicate the hallmark of MDS: myeloid dysplasia. MISTRG mice were engrafted with a primary MDS sample, RAEB I, with DNMT3a mutation. Mice were allowed to engraft for 16-20 weeks and analyzed for engraftment levels and signs of dysplasia. As evident in Figure   Figure 9 : MDS clonal hematopoiesis is represented and preserved in MISTRG mice: targeted exome sequencing. 10, histologic findings in engrafted MISTRG mice were those encountered in the patient at time of diagnosis. H&E reveals the presence of dysplastic megakaryocytes (MK) and the presence of fibrosis as well as absence of mature myeloid elements. Dysplastic megakaryocytes are highlighted by anti-huCD61 staining in the patient sample (top) and in engrafted MISTRG bone marrow. Reticulin fibrosis is markedly increase in the patient's and MISTRG bone marrow. Task 3b. Establish treatment protocols in (i) non-engrafted and then (ii) engrafted MISTRG mice . Drug treatment: We have successfully established a treatment protocol using standard chemotherapy in MISTRG mice. As opposed to NSG mice, MISTRG mice do not carry an inherent DNA repair defect, thus allowing the use of cytotoxic drugs. First studies have been performed in non-engrafted mice to assess toxicity of chemotherapeutic agents in MISTRG mice. MISTRG mice tolerated cytarabine (50mg/kg vs 100mg/kg, daily x 5 days) and doxorubicin (1.5mg/kg vs 3mg/kg, daily x 3days) alone and in combination without significant liver toxicity unlike NSG mice. However, main toxicity in MISTRG mice is hematopoietic toxicity and survival after chemotherapy administration is approximately 50%. 
Task 4. Develop a model to study MDS "disease-driving" mutations (mths 1-24):
Study individual mutations identified in our primary MDS samples by introduction of these mutations into human CD34+ stem and progenitor cells followed by in vitro and in vivo analysis 2a. Generation of inducible lentiviral vectors and in vitro analysis of transduced CD34+ cells. We have successfully cloned lentiviral vectors with inducible expression of WT and MUT SRSF2 and U2AF1, key splicing factors carrying point mutations in MDS. However, as our and the research of others has revealed, exogenous expression of mutant splicing factors does not provide the expected clonal advantage over wildtype cells. This has significantly limited our ability to engraft engineered CD34+ cells into MISTRG or NSG mice (data not shown) CRISPR/Cas mediated gene editing represents an attractive alternative to exogenous expression of mutant proteins and we have pursued this as an alternative strategy. These studies are now ongoing in follow-up to this proposal. To determine, whether MDS-MISTRG PDX allow the study of disease of specific driving mutations we selected MDS samples specifically based on their mutational spectrum and tested the effects of targeted therapeutics on MDS engraftment, blast percentage, and lineage differentiation. IDH2 mutations occur in approximately 20% of AML and 5% of MDS patients. They occur early in the disease process and promote loss of differentiation and progenitor expansion. Promising IDH2 inhibitors have been developed that are in clinical trials. We engrafted MISTRG mice with IDH2 mutant AML and MDS and subjected mice to short-and long-term treatments with vehicle or the IDH2 inhibitor AG221. IDH2 inhibition results in reduction in blast % and concomitant multilineage differentiation (Figure 12 ). Future projects aim at understanding the cooperativity between IDH mutations and other driver mutations as well as the effects of IDH2 inhibition on the MDS stem cell compartment. • Optimal transplantation technique into MISTRG for adult HSPCs has been established in regards to cell preparation, cell number, pre-transplant irradiation, and intrahepatic injection in d1-d3 old pups.
• Engraftment of adult HSPCs in MISTRG mice is superior to standard immunosufficient mice.
• Patient MDS bone marrow derived HSPCs successfully engraft MISTRG mice. An optimal transplantation model has been established.
• MISTRG give rise to multilineage engraftment and successful myeloid maturation.
• Engraftment of MDS HSPCs in MISTRG replicates the patient's immunophenotype.
• MISTRG mice lack the DNA repair defect inherent to NSG mice and are thus tolerant of chemotherapeutic agents allowing the testing of combination therapies.
• MISTRG mice engraft clonal MDS hematopoiesis as evident by cytogenetics, FISH, and targeted exome sequencing. Clonal distribution and mutant allele frequencies found in patients were preserved in our MDS-PDX model. • MISTRG mice supported robust myeloid engraftment and replicated the patients' MDS immunophenotypes while NSG mice had a higher frequency of lymphoid predominant grafts. Interestingly, overall MDS CD34 + cells result in higher myeloid engraftment than normal bone marrow in NSG and MISTRG (samples not age matched) as has been previously noted.
• Engrafted MISTRG bone marrows replicated the corresponding patient bone marrow findings, such as marked dysplasia and clustering of human CD61 positive megakaryocytes with resultant myelofibrosis as well as myeloid differentiation.
• MISTRG mice represent the ideal model for the development and testing of therapeutics targeted at MDS driver mutations. Inhibitors of mutant IDH2 reduce blast percentage in MISTRG mice transplanted with IDH2 mutant AML and high risk MDS and induce differentiation of myeloblasts as evident by upregulation of CD11b and CD15 (tested by flow Cytometry and histologic analysis).
Conclusion
MISTRG mice engraft low and high grade MDS with replication of the disease genotypes and phenotypes, supporting higher engraftment than NSG mice for all MDS samples assessed. We have developed a highly successful MDS xenotransplantation model in humanized immunodeficient mice that promises to become the new gold standard for in vivo MDS studies. This model represents the ideal platform to understand MDS biology and to decipher the response at the MDS stem cell level to targeted therapeutics.
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Manuscripts are in preparation + cell number and cell preparation. Mice were allowed to engraft for >10 weeks. Peripheral blood (PB), bone marrow (BM), and spleen were analyzed for engraftment by flow cytometry and tissues submitted for histologic analysis. HuCD45 + cells from engrafted MISTRG BM were subjected to targeted exome sequencing. MISTRG mice consistently supported higher engraftment in PB and BM than NSG mice for low and high grade MDS. On average, huCD45 engraftment was 7.3-fold higher in MISTRG than in NSG mice (17.78% vs. 2.45%) and 56.1% of MISTRG versus 26.7% of NSG mice were engrafted with improved preservation of clonal distribution and mutant allele frequencies. MISTRG as opposed to NSG mice supported robust myeloid engraftment and replicated the patients' MDS immunophenotype. Engrafted MISTRG bone marrows replicated the corresponding patient bone marrow findings, such as marked dysplasia and clustering of human CD61 positive megakaryocytes with resultant myelofibrosis. In conclusion, MISTRG mice engraft low and high grade MDS with replication of the disease genotypes and phenotypes, supporting higher engraftment than NSG mice for all MDS samples assessed. With lack of the DNA repair defect inherent to NSG mice MISTRG represent a promising "co-clinical" model of MDS to dissect disease mechanisms and for therapeutic testing. To establish a reliable, efficient MDS xenotransplantation model we optimized the host irradiation dose, transplantation route, CD34 + cell number and cell preparation. Mice were allowed to engraft for >10 weeks. Peripheral blood (PB), bone marrow (BM), and spleen were analyzed for engraftment by flow cytometry. BM, spleen, and liver were also fixed and sectioned for histologic analysis. Human CD45 + cells were sorted from engrafted MISTRG bone marrow and genomic testing was performed by cytogenetics, FISH, and/or targeted exome sequencing. MISTRG mice consistently supported higher engraftment in peripheral blood and bone marrow than NSG mice for the majority of MDS samples assessed. Out of 25 different patient's BM samples, including 6 RCMD, 5 RAEB I, 12 RAEB II, and 2 CMML patient samples, 23 samples engrafted in MISTRG mice, while 19 of the samples were transplanted concurrently into NSG mice (6 RCMD, 3 RAEB I, and 11 RAEB II patient samples) out of which 12 samples engrafted. Mice were classified as engrafted when huCD45 + cells accounted for over 1% of all nucleated cells in BM. On average, huCD45 engraftment was 7.3-fold higher in MISTRG than in NSG mice (17.78% vs. 2.45%). 56.1% of all MISTRG mice compared with 26.7% of NSG mice transplanted with MDS were engrafted. The number of engrafted MISTRG mice per sample ranged from 2-10 mice could be further improved with optimal bone marrow sample collection.
We verified engraftment of the MDS clone via cytogenetics, FISH, and/or targeted exome sequencing, also revealing preserved clonal distribution and mutant allele frequencies in engrafted mice. Flow cytometric analysis of lineage differentiation revealed robust myeloid engraftment in MISTRG mice as opposed to NSG mice. In addition terminal differentiation of myeloid cells was markedly improved in MISTRG over NSG mice, with immunophenotypic concordance between engrafted MISTRG mice and the patient's primary bone marrow. Histologic analysis showed striking similarities between engrafted MISTRG bone marrow and the concurrent patient's bone marrow, such as marked dysplasia and clustering of human CD61 positive megakarocytes with resultant myelofibrosis as evident by reticulin staining. MISTRG mice lack the DNA repair defect inherent to
